锦欣生殖：24H1海外业务快速增长，国内业务预计将受益于医保政策

研究报告 Research Report 10 Sep 2024 锦欣生殖 Jinxin Fertility (1951 HK) 24H1 海外业务快速增长，国内业务预计将受益于医保政策 In 24H1, overseas business saw rapid growth, and domestic operations are expected to benefit from medical insurance policies [Table_yemei 观点聚焦 1] Investment Focus | --- | --- | |---------------------------------------------------------------|-----------------------| | | | | [Table_Info] 维持优于大市 Maintain OUTPERFORM | | | 评级 | 优于大市 OUTPERFORM | | 现价 | HK$2.22 | | 目标价 | HK$3.69 | | HTI ESG | 3.9-3.2-3.0 | | E-S-G: 0-5, ...